Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The nCaF2-containing orthodontic primer is a bioactive dental material developed by researchers at the University of Baghdad to prevent white spot lesions (WSLs) during fixed orthodontic treatment. The formulation consists of calcium fluoride nanoparticles (nCaF2) at concentrations of 5%, 10%, or 20% by weight, incorporated into a conventional orthodontic primer (Transbond XT). The primer is designed to be applied to the enamel surface before bracket bonding. Its mechanism of action relies on the pH-responsive release of calcium and fluoride ions when the oral environment becomes acidic. These ions facilitate the remineralization of enamel by promoting the formation of fluorapatite crystals, which are more resistant to acid than hydroxyapatite. Additionally, the material aims to reduce the levels of cariogenic bacteria such as *Streptococcus mutans* on the tooth surface.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nCaF2-containing orthodontic primer.